# US 2020/0270637 A1 · Compositions and methods for inhibiting viral vector-induced inflammatory responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270637 A1
- Document ID: US20200270637A1
- Status: Published application
- Kind: A1
- Application number: 16/762,356
- Filed: 2018-11-08
- Published: 2020-08-27
- Earliest claimed: 2017-11-08
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Ying Kai Chan; George M. Church
- Web page: https://patentgrep.com/patent/US20200270637A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein, in some embodiments, are recombinant viral genomes comprising an inhibitory oligonucleotide that reduces inflammation for use, for example, in gene therapy.

## Claims

### Claim 1

A method comprising administering to a muscle tissue of a subject a recombinant viral genome comprising a therapeutic nucleotide sequence and an inhibitory oligonucleotide that inhibits nucleic acid-sensing toll-like receptor (TLR) activation and/or signaling, wherein the recombinant viral genome inhibits an inflammatory response to the recombinant viral genome in the muscle tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TLR is TLR9, optionally wherein at least one of the inhibitory oligonucleotides binds to TLR9, and optionally wherein at least one of the inhibitory oligonucleotides binds to TLR9 without activating TLR9 mediated signaling.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the recombinant viral genome is from adeno-associated virus (AAV), adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, or human parvovirus B19.

### Claim 4 (depends on 3)

The method of claim 3, wherein the recombinant viral genome is a recombinant AAV viral genome.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the recombinant viral genome is single stranded.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the recombinant viral genome is self-complementary.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the inhibitory oligonucleotide is located upstream from (5′) a promoter operably linked to the therapeutic nucleotide sequence, and optionally wherein the inhibitor oligonucleotides is located in a 5′ untranslated region (UTR) of the recombinant viral genome.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the inhibitory oligonucleotide is located downstream from (3′) a polyA tail linked to the therapeutic nucleic acid, and optionally wherein the inhibitor oligonucleotides is located in a 3′ UTR of the recombinant viral genome.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the recombinant viral genome further comprises at least one other inhibitory oligonucleotide that inhibits nucleic acid-sensing TLR activation and/or signaling, optionally wherein the inhibitory oligonucleotide are in different locations of the viral genome.

### Claim 10 (depends on 9)

The method of claim 9, wherein one of the inhibitory oligonucleotides is oriented in the sense direction of the recombinant viral genome and another of the inhibitory oligonucleotides is oriented in the antisense direction of the recombinant viral genome.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein at least one of the inhibitory oligonucleotides binds to inflammatory nucleic acids, optionally wherein the inhibitory oligonucleotide comprises CpG oligodeoxynucleotides.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein at least one of the inhibitory oligonucleotides comprises a CCx(not-C)(not-C)xxGGG motif, wherein x is any nucleic acid.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the inhibitory oligonucleotide comprises a nucleotide sequence that shares 90% to 100% identity with the nucleotide sequence of any one of SEQ ID NOS: 1-7, 9-25, or 27-32.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the inhibitory oligonucleotide comprises multiple tandem repeats, optionally 2 to 4 tandem repeats, of a nucleotide sequence that shares 90% to 100% identity with the nucleotide sequence of any one of SEQ ID NOS: 1-7, 9-25, or 27-32, optionally wherein the nucleotide sequences are separated from each other by a polyA linker.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the inhibitory oligonucleotide comprises the nucleotide sequence of SEQ ID NO: 35 (3×telomere).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the inhibitory oligonucleotide comprises the nucleotide sequence of SEQ ID NO: 39 (3×telo3×INH18).

### Claim 17 (depends on 9, 10)

The method of claim 9 or 10, wherein one of the inhibitory oligonucleotides comprises the nucleotide sequence of SEQ ID NO: 39 and one of the inhibitory oligonucleotide comprises the nucleotide sequence of SEQ ID NO: 40.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the inhibitory oligonucleotide comprises the nucleotide sequence of SEQ ID NO: 40 (3×4084-F3×2088).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the inhibitory oligonucleotide comprises at least one of the inhibitory oligonucleotides comprises at least one, at least two, at least three, or at least four TTAGGG (SEQ ID NO: 61) motif(s).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, the subject has a genetic disorder.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the therapeutic nucleotide sequence encodes a therapeutic nucleic acid, optionally a therapeutic RNA or a therapeutic DNA, or wherein the nucleotide sequence encodes a therapeutic protein or peptide.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the recombinant viral genome is administered in an amount that is at least 20% less than the amount of a control, optionally wherein the control is a recombinant viral genome that does not comprise an inhibitory oligonucleotide that inhibits nucleic acid-sensing TLR activation and/or signaling.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the recombinant viral genome is expressed in cells of the subject at a level that is at least 2-fold, at least 5-fold, at least 10-fold, or at least 15-fold greater than a control, optionally wherein the control is expression of a viral genome that does not comprise the inhibitory oligonucleotide.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein administration of the recombinant viral genome elicits an inflammatory response in the subject that is at least 2-fold, at least 5-fold, at least 10-fold, or at least 50-fold lower than a control, optionally wherein the control is expression of a viral genome that does not comprise the inhibitory oligonucleotide.

### Claim 25

A recombinant viral genome comprising a therapeutic nucleotide sequence and an inhibitory oligonucleotide that comprises the nucleotide sequence of any one of SEQ ID NOS: 2-5, 7, 10-25, or 27-32.

### Claim 26

A recombinant viral genome comprising a therapeutic nucleotide sequence and an inhibitory oligonucleotide that comprises the nucleotide sequence of SEQ ID NO: 35 (3×telomere), SEQ ID NO: 39 (3×telo3×INH18), and/or SEQ ID NO: 40 (3×4084-F3×2088).

### Claim 27 (depends on 25, 26)

The recombinant viral genome of claim 25 or 26, wherein the recombinant viral genome is from adeno-associated virus (AAV), adenovirus, herpes simplex virus, varicella, variola virus, hepatitis B, cytomegalovirus, JC polyomavirus, BK polyomavirus, monkeypox virus, Herpes Zoster, Epstein-Barr virus, human herpes virus 7, Kaposi's sarcoma-associated herpesvirus, or human parvovirus B19.

### Claim 28 (depends on 27)

The recombinant viral genome of claim 27, wherein the recombinant viral genome is a recombinant AAV viral genome.

### Claim 29 (depends on 25, 26, 27, 28)

The recombinant viral genome of any one of claims 25-28, wherein the recombinant viral genome is single stranded.

### Claim 30 (depends on 25, 26, 27, 28)

The recombinant viral genome of any one of claims 25-28, wherein the recombinant viral genome is self-complementary.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The recombinant viral genome of any one of claims 25-30, wherein the recombinant viral genome further comprises at least one other inhibitory oligonucleotide that inhibits nucleic acid-sensing TLR activation and/or signaling, optionally wherein the inhibitory oligonucleotide are in different locations of the viral genome.

### Claim 32 (depends on 25, 26, 27, 28, 29, 30, 31)

The recombinant viral genome of any one of claims 25-31, wherein the inhibitory oligonucleotide is located upstream from (5′) a promoter operably linked to the therapeutic nucleotide sequence, and optionally wherein the inhibitor oligonucleotides is located in a 5′ untranslated region (UTR) of the recombinant viral genome.

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The recombinant viral genome of any one of claims 25-32, wherein the inhibitory oligonucleotide is located downstream from (3′) a polyA tail linked to the therapeutic nucleic acid, and optionally wherein the inhibitor oligonucleotides is located in a 3′ UTR of the recombinant viral genome.

### Claim 34 (depends on 33)

The recombinant viral genome of claim 33, wherein one of the inhibitory oligonucleotides is oriented in the sense direction of the recombinant viral genome and another of the inhibitory oligonucleotides is oriented in the antisense direction of the recombinant viral genome.

### Claim 35 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A method comprising administering to a subject the recombinant viral genome of any one of claims 25-34, wherein the recombinant viral genome inhibits an inflammatory response to the recombinant viral genome in the subject.
